Familial Chylomicronemia Syndrome Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, Mechanism of Action, Route of Administration, and Developments | Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Familial Chylomicronemia Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ Familial Chylomicronemia Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Familial Chylomicronemia Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Familial Chylomicronemia Syndrome Market.

The Familial Chylomicronemia Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Familial Chylomicronemia Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Familial Chylomicronemia Syndrome treatment therapies with a considerable amount of success over the years.
• Familial Chylomicronemia Syndrome companies working in the treatment market are Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others, are developing therapies for the Familial Chylomicronemia Syndrome treatment
• Emerging Familial Chylomicronemia Syndrome therapies in the different phases of clinical trials are- ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others are expected to have a significant impact on the Familial Chylomicronemia Syndrome market in the coming years.
• In November 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for plozasiran, an investigational treatment for familial chylomicronemia syndrome (FCS), a rare and severe genetic disorder with no FDA-approved therapies. The company also plans to seek approval for plozasiran from other regulatory authorities in 2025.
• In April 2024, Ionis Pharmaceuticals is seeking regulatory approval for its lead candidate, olezarsen, following its success in achieving the primary endpoint in a pivotal trial for adults with familial chylomicronemia syndrome (FCS). The Phase III Balance trial, a global, multicenter, randomized, double-blind, placebo-controlled study (NCT04568434), included 66 participants aged 18 and older with confirmed FCS. Patients received olezarsen at doses of 80mg or 50mg, or a placebo, administered once every four weeks over a 53-week period.


Familial Chylomicronemia Syndrome Overview
Familial Chylomicronemia Syndrome (FCS) is a rare genetic disorder characterized by high levels of chylomicrons (fat particles) in the blood, leading to severe hypertriglyceridemia (elevated triglycerides). This condition results from mutations in the LPL (lipoprotein lipase) gene or other related genes involved in lipid metabolism. FCS can cause recurrent episodes of acute pancreatitis, abdominal pain, and other complications. The disorder is inherited in an autosomal recessive pattern, meaning both parents must carry a copy of the defective gene. Management often involves a strict low-fat diet, medications, and in some cases, treatments like lipid-lowering therapies or plasmapheresis.

Get a Free Sample PDF Report to know more about Familial Chylomicronemia Syndrome Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Familial Chylomicronemia Syndrome Drugs Under Different Phases of Clinical Development Include:
• ARO-APOC3: Arrowhead Pharma
• VSA001 injection: Visirna Therapeutics HK Limited
• Olezarsen: Ionis Pharmac
• LCQ908: Novartis
• AKCEA-ANGPTL3-LRx: Akcea Therapeutics
• Volanesorsen: Akcea Therapeutics
• Plozasiran: Arrowhead Pharmaceuticals

Familial Chylomicronemia Syndrome Route of Administration
Familial Chylomicronemia Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Familial Chylomicronemia Syndrome Molecule Type
Familial Chylomicronemia Syndrome Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Familial Chylomicronemia Syndrome Pipeline Therapeutics Assessment
• Familial Chylomicronemia Syndrome Assessment by Product Type
• Familial Chylomicronemia Syndrome By Stage and Product Type
• Familial Chylomicronemia Syndrome Assessment by Route of Administration
• Familial Chylomicronemia Syndrome By Stage and Route of Administration
• Familial Chylomicronemia Syndrome Assessment by Molecule Type
• Familial Chylomicronemia Syndrome by Stage and Molecule Type

DelveInsight's Familial Chylomicronemia Syndrome Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Familial Chylomicronemia Syndrome product details are provided in the report. Download the Familial Chylomicronemia Syndrome pipeline report to learn more about the emerging Familial Chylomicronemia Syndrome therapies at:
https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Familial Chylomicronemia Syndrome Therapeutics Market include:
Key companies developing therapies for Familial Chylomicronemia Syndrome are - Cumberland Pharmaceuticals, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc, Novartis, and others.

Familial Chylomicronemia Syndrome Pipeline Analysis:
The Familial Chylomicronemia Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Familial Chylomicronemia Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Chylomicronemia Syndrome Treatment.
• Familial Chylomicronemia Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Familial Chylomicronemia Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Chylomicronemia Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Familial Chylomicronemia Syndrome drugs and therapies-
https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Familial Chylomicronemia Syndrome Pipeline Market Drivers
• Increasing Awareness, Advancements in Gene Therapy, Improved Diagnostic Tools, Strong Pipeline Candidates, High Unmet Need, Collaborations and Partnerships, are some of the important factors that are fueling the Familial Chylomicronemia Syndrome Market.

Familial Chylomicronemia Syndrome Pipeline Market Barriers
• However, Limited Patient Population, High Treatment Costs, Regulatory Challenges, Long Development Timeline, Lack of Standardized Treatment Protocols, Insurance Reimbursement Issues , and other factors are creating obstacles in the Familial Chylomicronemia Syndrome Market growth.

Scope of Familial Chylomicronemia Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others
• Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others
• Familial Chylomicronemia Syndrome Therapeutic Assessment: Familial Chylomicronemia Syndrome current marketed and Familial Chylomicronemia Syndrome emerging therapies
• Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome market drivers and Familial Chylomicronemia Syndrome market barriers

Request for Sample PDF Report for Familial Chylomicronemia Syndrome Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Familial Chylomicronemia Syndrome Report Introduction
2. Familial Chylomicronemia Syndrome Executive Summary
3. Familial Chylomicronemia Syndrome Overview
4. Familial Chylomicronemia Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Familial Chylomicronemia Syndrome Pipeline Therapeutics
6. Familial Chylomicronemia Syndrome Late Stage Products (Phase II/III)
7. Familial Chylomicronemia Syndrome Mid Stage Products (Phase II)
8. Familial Chylomicronemia Syndrome Early Stage Products (Phase I)
9. Familial Chylomicronemia Syndrome Preclinical Stage Products
10. Familial Chylomicronemia Syndrome Therapeutics Assessment
11. Familial Chylomicronemia Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Familial Chylomicronemia Syndrome Key Companies
14. Familial Chylomicronemia Syndrome Key Products
15. Familial Chylomicronemia Syndrome Unmet Needs
16 . Familial Chylomicronemia Syndrome Market Drivers and Barriers
17. Familial Chylomicronemia Syndrome Future Perspectives and Conclusion
18. Familial Chylomicronemia Syndrome Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Familial Chylomicronemia Syndrome Market https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Familial Chylomicronemia Syndrome Epidemiology https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-epidemiology?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Familial Chylomicronemia Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.